NAMSA Acquires SUAZIO

NAMSA (ARCHIMED) Acquires Clinlogix

August 2, 2021

Healthcare Services

Toledo-based NAMSA, a portfolio company of healthcare-focused private equity firm ARCHIMED, has acquired Clinlogix, a Lower Gwynedd, Pennsylvania-based contract research organization (CRO) focused on medical device clinical trials. The deal expands NAMSA's clinical trial capacity by roughly 25%, deepens therapeutic expertise in neurology, oncology, urology and nephrology, and strengthens global trial capabilities with Clinlogix facilities in Japan, Germany and Colombia.

NAMSA Acquires Syntactx

January 5, 2021

Healthcare Services

NAMSA, a medical device–focused contract research organization (and portfolio company of ArchiMed), has acquired New York–based CRO Syntactx. The add-on purchase expands NAMSA’s clinical research, electronic data capture (EDC), core lab imaging, safety and cardiovascular regulatory consulting capabilities to better serve global medtech sponsors.

ArchiMed Acquires Majority Stake in NAMSA

September 1, 2020

Healthcare Services

ArchiMed, a healthcare-focused private equity firm, acquired a majority interest in NAMSA from the founding Gorski Family in an undisclosed equity recapitalization. NAMSA's president and senior management retained a significant double-digit stake; ArchiMed said the investment will support NAMSA's international growth and buy‑and‑build strategy to broaden services and accelerate expansion.

ARCHIMED (via MED Platform I) Acquires Majority Stake in SUANFARMA

November 18, 2021

Pharmaceuticals

Transatlantic healthcare-focused private equity firm ARCHIMED, through its MED Platform I (MPI) fund, has acquired a majority stake in Madrid-based SUANFARMA, a manufacturer and distributor of active pharmaceutical ingredients (APIs) and nutraceutical ingredients. Ares Management provided debt financing for the transaction; SUANFARMA founder Héctor Ara and members of management rolled a material minority stake into the business and remain significant shareholders.

NAMSA Acquires American Preclinical Services (APS)

March 2, 2021

Medical Devices

Toledo-based NAMSA, a medical-device-focused contract research organization owned by ARCHIMED's MED Platform I, has acquired Minneapolis-based American Preclinical Services (APS). The add-on expands NAMSA's lab, surgical instrumentation and imaging capabilities and increases its footprint in Minnesota; debt financing for the deal was provided by funds managed by Ares Management Corporation.

NAMSA Acquires WuXi AppTec U.S. Medical Device Testing Operations

January 17, 2025

Healthcare Services

NAMSA, an ARCHIMED-backed MedTech testing and clinical consulting firm, has acquired WuXi AppTec’s U.S. medical device testing operations (facilities in Minnesota and Georgia). The add-on expands NAMSA’s laboratory capacity and scientific capabilities across biocompatibility, microbiology, preclinical and extractables & leachables testing to better serve medical device manufacturers.